CAR-T Meeting 2024 | How frontline therapy impacts the management of patients with ALL prior to CAR-T
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the shift away from chemotherapy to agents such as inotuzumab ozogamicin and blinatumomab in the frontline setting for patients with acute lymphoblastic leukemia (ALL). Dr Barba also briefly comments on how the management of patients treated with blinatumomab prior to CAR-T will differ from those who are naïve to this agent. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So, classically, the management of frontline therapy for ALL patients was based only on chemotherapy, but now we have other agents like inotuzumab and blinatumomab especially, which is moving forward to the first line. We’ve seen several clinical trials in the past ASH meeting evaluating the use of blinatumomab in the first-line setting, and of course, this has important implications in the outcome of patients, the expression of CD19, and also in the safety and neurological complications of patients during blinatumomab...
So, classically, the management of frontline therapy for ALL patients was based only on chemotherapy, but now we have other agents like inotuzumab and blinatumomab especially, which is moving forward to the first line. We’ve seen several clinical trials in the past ASH meeting evaluating the use of blinatumomab in the first-line setting, and of course, this has important implications in the outcome of patients, the expression of CD19, and also in the safety and neurological complications of patients during blinatumomab.
So, the management of the patients who have received prior blinatumomab will need to be tailored and also [we must] look specifically at the risk factors in that population of patients, which apparently, based on the data that we have today, are not exactly the same as in patients that are blinatumomab naive. And, of course, the bridging therapy will need new strategies because these patients cannot receive those drugs that they have previously received in the first line.
Read more...
Disclosures
Allogene, Amgen, BMS/Celgene, Kite/Gilead, Incyte, Novartis, Pierre Fabre
